MyFinsight
Home
Blog
About
Net income
$237,007K
(147.94%↑ Y/Y)
Accrued expenses and
other payables
$212,435K
(180.91%↑ Y/Y)
Share-based compensation
expenses
$137,405K
(-44.21%↓ Y/Y)
Depreciation and
amortization expense
$40,515K
(-40.78%↓ Y/Y)
Accounts payable
$37,530K
(204.68%↑ Y/Y)
Acquired in-process
research and development
$20,518K
(4003.60%↑ Y/Y)
Net cash provided by
operating activities
$462,820K
(50.42%↑ Y/Y)
Effect of foreign
exchange rate changes,...
$19,836K
(-26.42%↓ Y/Y)
Canceled cashflow
$209,734K
Net increase in
cash, cash...
$427,249K
(189.98%↑ Y/Y)
Canceled cashflow
$55,407K
Accounts receivable
$117,576K
(60.25%↑ Y/Y)
Inventories
$47,150K
(863.69%↑ Y/Y)
Amortization of research and
development cost share...
-$29,518K
(35.22%↑ Y/Y)
Other assets
$11,377K
(-74.89%↓ Y/Y)
Other liabilities
-$4,113K
(-6526.56%↓ Y/Y)
Proceeds from sale or
maturity of investments
$5,845K
(224.72%↑ Y/Y)
Proceeds from option
exercises and employee...
$11,048K
(-88.55%↓ Y/Y)
Repayment of sale of future
royalties liability
-$1K
Net cash used in
investing activities
-$49,353K
(73.82%↑ Y/Y)
Net cash provided by
financing activities
-$6,054K
(-585.10%↓ Y/Y)
Canceled cashflow
$5,845K
Canceled cashflow
$11,049K
Purchases of property,
plant and equipment
$27,476K
(-72.59%↓ Y/Y)
Purchase of in-process
research and development
$20,518K
(-65.80%↓ Y/Y)
Other investing
activities
$7,204K
(-28.76%↓ Y/Y)
Repayment of long-term
loan
$17,052K
(1.51%↑ Y/Y)
Other financing
activities
-$51K
Back
Back
Cash Flow
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)
source: myfinsight.com